Correction: Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer

Mariya Shapovalova; Julia Davydova; Christine Henzler; Mark Daniel; Scott M. Dehm; Christopher A. Warlick; Aaron M. LeBeau

doi:10.18632/oncotarget.27143

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer

PDF | How to cite

Oncotarget. 2019; 10:4920-4920. https://doi.org/10.18632/oncotarget.27143

Metrics: PDF 1374 views | ?

Mariya Shapovalova¹, Julia Davydova², Christine Henzler³, Mark Daniel⁴, Scott M. Dehm³, Christopher A. Warlick⁵ and Aaron M. LeBeau¹

¹ Department of Pharmacology, University of Minnesota, Minneapolis 55455, MN, USA
² Department of Surgery, University of Minnesota, Minneapolis 55455, MN, USA
³ Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis 55455, MN, USA
⁴ Department of Microbiology and Immunology, University of Minnesota, Minneapolis 55455, MN, USA
⁵ Department of Urology, University of Minnesota, Minneapolis 55455, MN, USA

Published: August 06, 2019

This article has been corrected: The proper Grant Support information is shown below:

GRANT SUPPORT

This research was supported by a Department of Defense Prostate Cancer Research Program Early Investigator Research Award – Predoctoral (MS), Prostate Cancer Foundation Young Investigator Award (AML), Randy Shaver Foundation Research Award (AML), Paul Calabresi NCI K12 Award through Mayo Clinic (AML) and an American Cancer Society Institutional Research Grant (AML).

Original article: Oncotarget. 2018; 9:36693–36704. DOI: https://doi.org/10.18632/oncotarget.26401.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27143

Publication Alerts

Oncoscience

Post-Publication Promotion

Corrections:

Correction: Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer